A Phase I/II Single-Blinded Randomized Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID 19
Latest Information Update: 06 Jun 2022
At a glance
- Drugs AZD 1222 (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary)
- Indications COVID 2019 infections
- Focus Pharmacodynamics
- Sponsors R-Pharm
- 02 Jun 2022 Status changed from recruiting to completed.
- 20 Sep 2021 Status changed from not yet recruiting to recruiting.
- 01 Jul 2021 Planned End Date changed from 12 Oct 2021 to 8 Apr 2022.